2023.06.02

Hanshin Medipia will adopt Monitor Corporation's AI-based chest CT analysis solution for lung cancer diagnosis. The two companies signed an MOU to implement the AI solution, which is the first of its kind to receive Class 3 approval from the Ministry of Food and Drug Safety in Korea.
Hanshin Medipia, despite having advanced imaging equipment, faced challenges in analyzing large volumes of CT data for lung cancer diagnosis. With this AI solution, they aim to offer more precise and faster lung cancer screenings, enhancing patient care.
Dr. Kang Han-seung, Director of Hanshin Medipia, and CEO Lee Kyung-joon of Monitor Corporation both expressed their commitment to improving healthcare services through this partnership.
See full Korean article at digitalchosun